生物制剂治疗免疫检查点抑制剂相关性结肠炎的研究进展  

Research progress of biologics for the treatment of immune checkpoint inhibitor-induced colitis

作　　者：刘玲[2] 董文逍 王邦茂[1] 曹海龙[1] Liu Ling;Dong Wenxiao;Wang Bangmao;Cao Hailong(Department of Gastroenterology,Tianjin Medical University General Hospital,Tianjin 300070,China;Department of Pharmacy,Puyang People's Hospital of Henan Province,Puyang 457000,China)

机构地区：[1]天津医科大学总医院消化科,天津300070 [2]河南省濮阳市人民医院药剂科,濮阳457000

出　　处：《中华炎性肠病杂志（中英文）》2023年第4期355-359,共5页Chinese Journal of Inflammatory Bowel Diseases

基　　金：国家自然科学基金(82270574、82070545)。

摘　　要：近年来, 免疫检查点抑制剂(ICIs)广泛应用于多种肿瘤的治疗。然而ICIs相关性结肠炎是导致免疫治疗中断、永久停用和治疗相关死亡的最常见原因。糖皮质激素是ICIs相关性结肠炎一线治疗方案, 如出现糖皮质激素无反应或不耐受, 可考虑选择生物制剂治疗。尽管ICIs相关性结肠炎与炎症性肠病有相似之处, 但它被认为是一种不同形式的结肠炎, 前者起病较急, 可迅速出现肠梗阻、巨结肠、腹膜炎、肠穿孔和死亡等, 及时识别和管理至关重要。本文就生物制剂在治疗ICIs相关性结肠炎时的疗效、安全性及对ICIs抗肿瘤治疗效果的影响等方面研究进展进行综述。Recently immune checkpoint inhibitors(ICIs)have been widely used in the treatment of tumors.ICIs-induced colitis is the most common cause of immunotherapy interruption,permanent discontinuation and treatment-related death.Corticosteroids are the first-line therapy.If there is no response or intolerance to corticosteroid,biologics can be selected for treatment.Although there are similarities between ICIs-induced colitis and inflammatory bowel disease,it is considered to be a different form of colitis with a more acute onset,which can rapidly deteriorate into ileus,megacolon,peritonitis,intestinal perforation,or even death.Timely recognition and management are crucial.This review summarizes the efficacy and safety of biological agents in the treatment of ICIs-induced colitis and their influence on the anti-tumor effects of ICIs.

关 键 词：免疫检查点抑制剂 结肠炎 生物制剂 

分 类 号：R574.62[医药卫生—消化系统]